medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2010, Number 3

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2010; 8 (3)

Primary cutaneous melanoma: An update depicting the importance in early detection and treatment by the dermatologist (Part one)

Aguilar DA, Asz SD, Fonte ÁV, Domínguez CJ

Language: Spanish
References: 111
Page: 203-209
PDF size: 388.20 Kb.


ABSTRACT

Melanoma is a malignant tumor derived from a group of cells called melanocites. It is the cancer with the highest worldwide prevalence and presents many risk factors and clinical forms.


REFERENCES

  1. Swetter S. Malignant melanoma. En http://wwweMedicine.com, enero de 2008.

  2. Sober A, Chuang T, Duvic M y cols. ”Guidelines of care for primary cutaneous melanoma”. J Am Acad Dermatol 2001; 45: 579-586.

  3. Urist M, Soong S. “Melanoma and cutaneous malignancies”. En: Sabiston, Textbook of surgery, 18a ed, Filadelfia, Saunders, 2008, 241-256.

  4. Sampsel JW, Barbera-Guillem E. “Management of cutaneous melanoma”. N Engl J Med 2004; 351 (10): 998-1012.

  5. Wolff K, Goldsmith L, Katz S, Gilchrest B, Paller A, Leffel D, Fitzpatrick’s. Neoplasms: Cutaneous melanoma. Dermatology in general medicine, 7a ed, McGraw-Hill, 2008.

  6. Desmond RA, Soong SJ. “Epidemiology of malignant melanoma”. Surg Clin North Am 2003; 83 (1): 1-29.

  7. PAC-MG. Programa de actualización continua para el dermatólogo, libro 9, 1a ed, 2000.

  8. Parada RJ, Corona PB, Dorantes GL. Melanoma maligno cutáneo. Perfil epidemiológico en México. GAMO 2003; 17-22.

  9. Martínez-Said H, Cuellar-Hubbe M, Barrón Velásquez E y cols. “Epidemiology of cutaneous melanoma in México (1980-2002)”. Eur J Surg Oncol 2004; 30 (2): 163.

  10. MacKie RM, Hauschild A, Eggermon AMM. “Epidemiology of invasive cutaneous melanoma”. Ann Oncol 2009; 20 (supl. 6): vi1-vi7.

  11. Diffey BL. “The future incidence of cutaneous melanoma within the UK”. Br J Dermatol 2004; 151: 868–872.

  12. De Vries E, Van de Poll-Franse LV, Louwman WJ y cols. “Predictions of skin cancer incidence in the Netherlands up to 2015”. Br J Dermatol 2005; 152: 481-488.

  13. Miller AJ, Mihm MC Jr. “Melanoma”. N Engl J Med 2006; 355 (1): 51-65.

  14. Oliveria SA, Sachs D, Belasco KT y cols. “Adoption of new technologies for early detection of melanoma in dermatologic practice”. J Am Acad Dermatol 2003; 49 (5): 955-959.

  15. Swetter S. “Dermatological perspectives of malignant melanoma”. Surg Clin North Am 2003; 83 (1): 77-95.

  16. Thompson JF, Scolyer RA, Kefford RF. “Cutaneous melanoma”. Lancet 2005; 365: 687-701.

  17. Dong J, Phelps RG, Qiao R y cols. “BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma”. Cancer Res 2003; 63: 3883-3885.

  18. Pollock PM, Harper UL, Hansen KS y cols. ”High frequency of BRAF mutations in nevi”. Nat Genet 2003; 33: 19-20.

  19. Uribe P, Wistuba II, Gonzalez S. “BRAF mutation: A frequent event in benign, atypical, and malignant melanocytic lesions of the skin”. Am J Dermatopathol 2003; 25: 365-370.

  20. Sharpless E, Chin L. “The INK4a/ARF locus and melanoma”. Oncogene 2003; 22: 3092-3098.

  21. Binni F, Antigoni I, De Simone P y cols. “Novel and recurrent p14 (ARF) mutations in Italian familial melanoma”. Clin Genet 2010. Publicado en internet antes de imprimirse.

  22. Gudbjartsson DF, Sulem P, Stacey SN y cols. ”ASIP and TYR pigmentation variants associated with cutaneous melanoma and basal cell carcinoma”. Nat Genet 2008; 40: 886-891.

  23. Aleifrán Ruiz A, Escobar Alfaro. “Epidemiología del melanoma de piel en México”. Rev Inst Nal Cancerol 1998; 44 (4): 168-174.

  24. Magaña García M. “Melanoma maligno: Aspectos clínicos en la población mexicana”. Dermatología 1991; 35: 313.

  25. Rodríguez CS, Labastida AS. “Aspectos epidemiológicos del melanoma en México”. Cir Cirujanos 1994; 61: 64.

  26. Alonso S, Ortiz P, Pollán M y cols. “Progression in cutaneous malignant melanoma is associated with distinct expression profiles: A tissue microarray-based study”. Am J Pathol 2004; 164: 193-203.

  27. Albreski D, Sloan SB. “Melanoma of the feet: Misdiagnosed and misunderstood”. Clinics in Dermatology 2009; 27: 556-563.

  28. Duncan LM. “The classification of cutaneous melanoma”. Hematol Oncol Clin North Am 2009; 23 (3): 501-513.

  29. Chamberlain A, Ng J. “Cutaneous melanoma—atypical variants and presentations”. Aust Fam Physician 2009; 38 (7): 476-482.

  30. Liu W, Dowling JP, Murray W y cols. “Rate of growth in melanomas: Characteristics and associations of rapidly growing melanomas”. Arch Dermatol 2006; 142: 1551-1558.

  31. Kelly JW, Chamberlain AJ, Staples MP y cols. “Nodular melanoma—no longer as simple as ABC”. Aust Fam Physician 2003; 32: 706-709.

  32. Weyers W, Euler M, Diaz-Cascajo C, Schill WB, Bonczkowitz M. “Classification of cutaneous malignant melanoma: A reassessment of histopathologic criteria for the distinction of different types”. Cancer 1999; 86: 288-299.

  33. Feibleman CE, Stoll H, Maize JC. “Melanomas of the palm, sole, and nailbed: A clinicopathologic study”. Cancer 1980; 46: 2492-2504.

  34. Kaskel P, Kind P, Sander S y cols. “Trauma and melanoma formation: A true association?” Br J Dermatol 2000; 143: 749-753.

  35. Baran R, Kechijian P. “Hutchinson’s sign: A reappraisal”. J Am Acad Dermatol 1996; 34 (1): 87-90.

  36. Socrier Y, Lauwers-Cances V, Lamant L y cols. “Histological regression in primary melanoma: Not a predictor of sentinel lymph node metastasis in a cohort of 397 patients”. Br J Dermatol 2009. Publicado en internet antes de imprimirse.

  37. Requena C, Botella-Estrada R, Traves V y cols. “Problems in defining melanoma regression and prognostic implication”. Actas Dermosifiliogr 2009; 100 (9): 759-766.

  38. Swetter S. Malignant melanoma. En http://wwweMedicine.com, enero de 2008.

  39. Sober A, Chuang T, Duvic M y cols. ”Guidelines of care for primary cutaneous melanoma”. J Am Acad Dermatol 2001; 45: 579-586.

  40. Urist M, Soong S. “Melanoma and cutaneous malignancies”. En: Sabiston, Textbook of surgery, 18a ed, Filadelfia, Saunders, 2008, 241-256.

  41. Sampsel JW, Barbera-Guillem E. “Management of cutaneous melanoma”. N Engl J Med 2004; 351 (10): 998-1012.

  42. Wolff K, Goldsmith L, Katz S, Gilchrest B, Paller A, Leffel D, Fitzpatrick’s. Neoplasms: Cutaneous melanoma. Dermatology in general medicine, 7a ed, McGraw-Hill, 2008.

  43. Desmond RA, Soong SJ. “Epidemiology of malignant melanoma”. Surg Clin North Am 2003; 83 (1): 1-29.

  44. PAC-MG. Programa de actualización continua para el dermatólogo, libro 9, 1a ed, 2000.

  45. Parada RJ, Corona PB, Dorantes GL. Melanoma maligno cutáneo. Perfil epidemiológico en México. GAMO 2003; 17-22.

  46. Martínez-Said H, Cuellar-Hubbe M, Barrón Velásquez E y cols. “Epidemiology of cutaneous melanoma in México (1980-2002)”. Eur J Surg Oncol 2004; 30 (2): 163.

  47. MacKie RM, Hauschild A, Eggermon AMM. “Epidemiology of invasive cutaneous melanoma”. Ann Oncol 2009; 20 (supl. 6): vi1-vi7.

  48. Diffey BL. “The future incidence of cutaneous melanoma within the UK”. Br J Dermatol 2004; 151: 868–872.

  49. De Vries E, Van de Poll-Franse LV, Louwman WJ y cols. “Predictions of skin cancer incidence in the Netherlands up to 2015”. Br J Dermatol 2005; 152: 481-488.

  50. Miller AJ, Mihm MC Jr. “Melanoma”. N Engl J Med 2006; 355 (1): 51-65.

  51. Oliveria SA, Sachs D, Belasco KT y cols. “Adoption of new technologies for early detection of melanoma in dermatologic practice”. J Am Acad Dermatol 2003; 49 (5): 955-959.

  52. Swetter S. “Dermatological perspectives of malignant melanoma”. Surg Clin North Am 2003; 83 (1): 77-95.

  53. Thompson JF, Scolyer RA, Kefford RF. “Cutaneous melanoma”. Lancet 2005; 365: 687-701.

  54. Dong J, Phelps RG, Qiao R y cols. “BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma”. Cancer Res 2003; 63: 3883-3885.

  55. Pollock PM, Harper UL, Hansen KS y cols. ”High frequency of BRAF mutations in nevi”. Nat Genet 2003; 33: 19-20.

  56. Uribe P, Wistuba II, Gonzalez S. “BRAF mutation: A frequent event in benign, atypical, and malignant melanocytic lesions of the skin”. Am J Dermatopathol 2003; 25: 365-370.

  57. Sharpless E, Chin L. “The INK4a/ARF locus and melanoma”. Oncogene 2003; 22: 3092-3098.

  58. Binni F, Antigoni I, De Simone P y cols. “Novel and recurrent p14 (ARF) mutations in Italian familial melanoma”. Clin Genet 2010. Publicado en internet antes de imprimirse.

  59. Gudbjartsson DF, Sulem P, Stacey SN y cols. ”ASIP and TYR pigmentation variants associated with cutaneous melanoma and basal cell carcinoma”. Nat Genet 2008; 40: 886-891.

  60. Aleifrán Ruiz A, Escobar Alfaro. “Epidemiología del melanoma de piel en México”. Rev Inst Nal Cancerol 1998; 44 (4): 168-174.

  61. Magaña García M. “Melanoma maligno: Aspectos clínicos en la población mexicana”. Dermatología 1991; 35: 313.

  62. Rodríguez CS, Labastida AS. “Aspectos epidemiológicos del melanoma en México”. Cir Cirujanos 1994; 61: 64.

  63. Alonso S, Ortiz P, Pollán M y cols. “Progression in cutaneous malignant melanoma is associated with distinct expression profiles: A tissue microarray-based study”. Am J Pathol 2004; 164: 193-203.

  64. Albreski D, Sloan SB. “Melanoma of the feet: Misdiagnosed and misunderstood”. Clinics in Dermatology 2009; 27: 556-563.

  65. Duncan LM. “The classification of cutaneous melanoma”. Hematol Oncol Clin North Am 2009; 23 (3): 501-513.

  66. Chamberlain A, Ng J. “Cutaneous melanoma—atypical variants and presentations”. Aust Fam Physician 2009; 38 (7): 476-482.

  67. Liu W, Dowling JP, Murray W y cols. “Rate of growth in melanomas: Characteristics and associations of rapidly growing melanomas”. Arch Dermatol 2006; 142: 1551-1558.

  68. Kelly JW, Chamberlain AJ, Staples MP y cols. “Nodular melanoma—no longer as simple as ABC”. Aust Fam Physician 2003; 32: 706-709.

  69. Weyers W, Euler M, Diaz-Cascajo C, Schill WB, Bonczkowitz M. “Classification of cutaneous malignant melanoma: A reassessment of histopathologic criteria for the distinction of different types”. Cancer 1999; 86: 288-299.

  70. Feibleman CE, Stoll H, Maize JC. “Melanomas of the palm, sole, and nailbed: A clinicopathologic study”. Cancer 1980; 46: 2492-2504.

  71. Kaskel P, Kind P, Sander S y cols. “Trauma and melanoma formation: A true association?” Br J Dermatol 2000; 143: 749-753.

  72. Baran R, Kechijian P. “Hutchinson’s sign: A reappraisal”. J Am Acad Dermatol 1996; 34 (1): 87-90.

  73. Socrier Y, Lauwers-Cances V, Lamant L y cols. “Histological regression in primary melanoma: Not a predictor of sentinel lymph node metastasis in a cohort of 397 patients”. Br J Dermatol 2009. Publicado en internet antes de imprimirse.

  74. Requena C, Botella-Estrada R, Traves V y cols. “Problems in defining melanoma regression and prognostic implication”. Actas Dermosifiliogr 2009; 100 (9): 759-766.

  75. Swetter S. Malignant melanoma. En http://wwweMedicine.com, enero de 2008.

  76. Sober A, Chuang T, Duvic M y cols. ”Guidelines of care for primary cutaneous melanoma”. J Am Acad Dermatol 2001; 45: 579-586.

  77. Urist M, Soong S. “Melanoma and cutaneous malignancies”. En: Sabiston, Textbook of surgery, 18a ed, Filadelfia, Saunders, 2008, 241-256.

  78. Sampsel JW, Barbera-Guillem E. “Management of cutaneous melanoma”. N Engl J Med 2004; 351 (10): 998-1012.

  79. Wolff K, Goldsmith L, Katz S, Gilchrest B, Paller A, Leffel D, Fitzpatrick’s. Neoplasms: Cutaneous melanoma. Dermatology in general medicine, 7a ed, McGraw-Hill, 2008.

  80. Desmond RA, Soong SJ. “Epidemiology of malignant melanoma”. Surg Clin North Am 2003; 83 (1): 1-29.

  81. PAC-MG. Programa de actualización continua para el dermatólogo, libro 9, 1a ed, 2000.

  82. Parada RJ, Corona PB, Dorantes GL. Melanoma maligno cutáneo. Perfil epidemiológico en México. GAMO 2003; 17-22.

  83. Martínez-Said H, Cuellar-Hubbe M, Barrón Velásquez E y cols. “Epidemiology of cutaneous melanoma in México (1980-2002)”. Eur J Surg Oncol 2004; 30 (2): 163.

  84. MacKie RM, Hauschild A, Eggermon AMM. “Epidemiology of invasive cutaneous melanoma”. Ann Oncol 2009; 20 (supl. 6): vi1-vi7.

  85. Diffey BL. “The future incidence of cutaneous melanoma within the UK”. Br J Dermatol 2004; 151: 868–872.

  86. De Vries E, Van de Poll-Franse LV, Louwman WJ y cols. “Predictions of skin cancer incidence in the Netherlands up to 2015”. Br J Dermatol 2005; 152: 481-488.

  87. Miller AJ, Mihm MC Jr. “Melanoma”. N Engl J Med 2006; 355 (1): 51-65.

  88. Oliveria SA, Sachs D, Belasco KT y cols. “Adoption of new technologies for early detection of melanoma in dermatologic practice”. J Am Acad Dermatol 2003; 49 (5): 955-959.

  89. Swetter S. “Dermatological perspectives of malignant melanoma”. Surg Clin North Am 2003; 83 (1): 77-95.

  90. Thompson JF, Scolyer RA, Kefford RF. “Cutaneous melanoma”. Lancet 2005; 365: 687-701.

  91. Dong J, Phelps RG, Qiao R y cols. “BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma”. Cancer Res 2003; 63: 3883-3885.

  92. Pollock PM, Harper UL, Hansen KS y cols. ”High frequency of BRAF mutations in nevi”. Nat Genet 2003; 33: 19-20.

  93. Uribe P, Wistuba II, Gonzalez S. “BRAF mutation: A frequent event in benign, atypical, and malignant melanocytic lesions of the skin”. Am J Dermatopathol 2003; 25: 365-370.

  94. Sharpless E, Chin L. “The INK4a/ARF locus and melanoma”. Oncogene 2003; 22: 3092-3098.

  95. Binni F, Antigoni I, De Simone P y cols. “Novel and recurrent p14 (ARF) mutations in Italian familial melanoma”. Clin Genet 2010. Publicado en internet antes de imprimirse.

  96. Gudbjartsson DF, Sulem P, Stacey SN y cols. ”ASIP and TYR pigmentation variants associated with cutaneous melanoma and basal cell carcinoma”. Nat Genet 2008; 40: 886-891.

  97. Aleifrán Ruiz A, Escobar Alfaro. “Epidemiología del melanoma de piel en México”. Rev Inst Nal Cancerol 1998; 44 (4): 168-174.

  98. Magaña García M. “Melanoma maligno: Aspectos clínicos en la población mexicana”. Dermatología 1991; 35: 313.

  99. Rodríguez CS, Labastida AS. “Aspectos epidemiológicos del melanoma en México”. Cir Cirujanos 1994; 61: 64.

  100. Alonso S, Ortiz P, Pollán M y cols. “Progression in cutaneous malignant melanoma is associated with distinct expression profiles: A tissue microarray-based study”. Am J Pathol 2004; 164: 193-203.

  101. Albreski D, Sloan SB. “Melanoma of the feet: Misdiagnosed and misunderstood”. Clinics in Dermatology 2009; 27: 556-563.

  102. Duncan LM. “The classification of cutaneous melanoma”. Hematol Oncol Clin North Am 2009; 23 (3): 501-513.

  103. Chamberlain A, Ng J. “Cutaneous melanoma—atypical variants and presentations”. Aust Fam Physician 2009; 38 (7): 476-482.

  104. Liu W, Dowling JP, Murray W y cols. “Rate of growth in melanomas: Characteristics and associations of rapidly growing melanomas”. Arch Dermatol 2006; 142: 1551-1558.

  105. Kelly JW, Chamberlain AJ, Staples MP y cols. “Nodular melanoma—no longer as simple as ABC”. Aust Fam Physician 2003; 32: 706-709.

  106. Weyers W, Euler M, Diaz-Cascajo C, Schill WB, Bonczkowitz M. “Classification of cutaneous malignant melanoma: A reassessment of histopathologic criteria for the distinction of different types”. Cancer 1999; 86: 288-299.

  107. Feibleman CE, Stoll H, Maize JC. “Melanomas of the palm, sole, and nailbed: A clinicopathologic study”. Cancer 1980; 46: 2492-2504.

  108. Kaskel P, Kind P, Sander S y cols. “Trauma and melanoma formation: A true association?” Br J Dermatol 2000; 143: 749-753.

  109. Baran R, Kechijian P. “Hutchinson’s sign: A reappraisal”. J Am Acad Dermatol 1996; 34 (1): 87-90.

  110. Socrier Y, Lauwers-Cances V, Lamant L y cols. “Histological regression in primary melanoma: Not a predictor of sentinel lymph node metastasis in a cohort of 397 patients”. Br J Dermatol 2009. Publicado en internet antes de imprimirse.

  111. Requena C, Botella-Estrada R, Traves V y cols. “Problems in defining melanoma regression and prognostic implication”. Actas Dermosifiliogr 2009; 100 (9): 759-766.




2020     |     www.medigraphic.com